There are no clearly defined genetic or environmental risk factors.[2]Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019 Aug;18(8):784-94.
http://www.ncbi.nlm.nih.gov/pubmed/31076244?tool=bestpractice.com
Infection, immunisation, or surgical procedures precede CIDP in approximately 10% to 30% of patients.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30.
http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com
[6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53.
http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
[17]Rajabally YA, Peric S, Bozovic I, et al. Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study. Muscle Nerve. 2021 Dec;64(6):657-61.
http://www.ncbi.nlm.nih.gov/pubmed/34263956?tool=bestpractice.com
There is an increased incidence of CIDP in patients with diabetes mellitus, and severity of CIDP may be worse in these patients.[18]Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016 Sep-Oct;30(7):1401-7.
https://www.sciencedirect.com/science/article/pii/S1056872716301349
http://www.ncbi.nlm.nih.gov/pubmed/27389526?tool=bestpractice.com
[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full
http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com
[20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9.
https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf
http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
CIDP can also occur in association with infection, including HIV.[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full
http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com
[20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9.
https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf
http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
About 10% to 15% of patients have a benign monoclonal gammopathy of undetermined significance (MGUS), most often with an IgA or IgG paraprotein; MGUS may affect disease course and response to treatment.[2]Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019 Aug;18(8):784-94.
http://www.ncbi.nlm.nih.gov/pubmed/31076244?tool=bestpractice.com
[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full
http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com
[20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9.
https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf
http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
CIDP may also co-exist with other autoimmune diseases, such as systemic lupus erythematosus, connective tissue disease, inflammatory bowel disease, thyroid disease, sarcoidosis, glomerulonephritis, chronic active hepatitis, or graft-versus-host disease.[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full
http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com
[20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9.
https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf
http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com